10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

18 November 2020 - Event

XIV European Patients’ Rights Day 2020 – Public and private sector challenges to address the “the Silent Tsunami”

The XIV European Patients’ Rights Day (EPRD) will be celebrated by Active Citizenship Network (ACN) with a virtual multi-stakeholder conference which, this year, focuses…

17 November 2020 - Event

Fixing the antibiotic innovation pipeline; Online discussion hosted by the MEP Interest Group on AMR

The current antibiotic innovation pipeline is broken. The last antibiotic class that was successfully introduced as a treatment was discovered…

19 November 2020 - Event

XIV European Patients’ Rights Day 2020 – Towards an AMR citizens’ alliance

The XIV European Patients’ Rights Day (EPRD) will be celebrated by Active Citizenship Network (ACN) with a virtual multi-stakeholder conference which, this year, focuses…

BEAM News
Member News
Events

Latest news of BEAM Alliance

18 November 2020 - BEAM Alliance

2020 Antimicrobial Resistance campaign: How to change the fight against AMR?

The BEAM Alliance recently worked with Global Cause on the 2020 Antimicrobial Resistance campaign.

09 November 2020 - BEAM Alliance

Antibiorésistance : Anticiper une nouvelle crise sanitaire

Florence Séjourné, présidente de BEAM Alliance : « Il faut anticiper les investissements en R&D dès maintenant pour avoir un…

28 August 2020 - BEAM Alliance

BEAM Alliance and global partners call for urgent action on new reimbursement models for life-saving antibiotics

27 August 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the AMR Action Fund

The COVID-19 pandemic has stressed how drug and vaccine development requires time and resources. Whilst we welcome the launch of…

10 July 2020 - BEAM Alliance

BEAM Alliance – Reflection paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

02 April 2020 - BEAM Alliance

Request for Proposals (RFP) for an Agreement for Performance of Work (APW) to develop an online e-learning course on antimicrobial stewardship

To support the Antimicrobial Stewardship and Awareness (ASA) Unit in the Global Coordination and Partnership on Antimicrobial Resistance (GCP) department…

page 1/4

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

12 January 2021 - BioVersys AG

BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BVL-GSK098

BioVersys AG is a privately-owned clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on…

22 December 2020 - MaaT Pharma

MaaT Pharma Announces First Positive DSMB Safety Review for Phase Ib CIMON Trial Testing Its Microbiome Ecosystem Therapy Capsule Formulation in AML Patients

MaaT033 is an oral, full-ecosystem, off-the-shelf, standardized, pooled-donor, high-richness microbiome biotherapeutic. It is manufactured at MaaT Pharma’s centralized European cGMP…

22 December 2020 - Polyphor Ltd

Polyphor receives approval to start first-in-human clinical trial of inhaled antibiotic murepavadin

Polyphor's inhaled murepavadin is currently being developed as a precision antibiotic specifically for the treatment of chronic Pseudomonas aeruginosa infections…

21 December 2020 - Aptorum Group Ltd

Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel first-in-class orally administered small molecule drug based…

21 December 2020 - ALLECRA THERAPEUTICS

Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China

Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming…

14 December 2020 - Polyphor Ltd

Polyphor announces third positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III balixafortide FORTRESS study without modifications

Polyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing first-in-class molecules in oncology and antimicrobial resistance…

page 1/26

Events

22 March 2021

BIO-Europe Spring® Digital — 15th International Partnering Conference

The fifteenth annual BIO-Europe Spring® conference is the premier springtime partnering conference for the life science industry. For its 2021…

25 February 2021

REVIVE Webinar: From discovery to the pre-clinical antimicrobial candidate

REVIVE is a space for everybody with an interest in antimicrobial R&D. The Global Antibiotic Research and Development Partnership (GARDP)…

14 January 2021

REVIVE Webinar: Manipulating the host response to treat infections

Presentations: 1.) Immune modulation and host directed therapies as an adjunctive approach to treating infections (R.E.W. (Bob) Hancock): - Host…

11 January 2021

Biotech Showcase™ Digital 2021

Biotech Showcase™ Digital is an investor and networking conference devoted to providing private and small- and mid-cap biotechnology companies an…

20 November 2020

REVIVE Webinar: Saving childrens’ lives – treating neonatal sepsis

The webinar, organized in collaboration with WHO, is being held on the occasion of Universal Children’s Day and during World…

19 November 2020

XIV European Patients’ Rights Day 2020 – Towards an AMR citizens’ alliance

The XIV European Patients’ Rights Day (EPRD) will be celebrated by Active Citizenship Network (ACN) with a virtual multi-stakeholder conference which, this year, focuses…

18 November 2020

XIV European Patients’ Rights Day 2020 – Public and private sector challenges to address the “the Silent Tsunami”

The XIV European Patients’ Rights Day (EPRD) will be celebrated by Active Citizenship Network (ACN) with a virtual multi-stakeholder conference which, this year, focuses…

17 November 2020

REVIVE Webinar: Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)

In this webinar, the speakers will give an overview of their work on the discovery of antibiotics through the use…

17 November 2020

Fixing the antibiotic innovation pipeline; Online discussion hosted by the MEP Interest Group on AMR

The current antibiotic innovation pipeline is broken. The last antibiotic class that was successfully introduced as a treatment was discovered…

page 1/9